Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Multiple Myeloma 10Neoplasms 8Lymphoma 7Carcinoma, Non-Small-Cell Lung 7Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 5Neoplasms, Plasma Cell 4Advanced Solid Tumors 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Melanoma 3Lung Neoplasms 3Leukemia 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Solid Tumors 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1

Interventions

palbociclib 2duvelisib 2berzosertib 2Fulvestrant 2Everolimus 2volagidemab 1serabelisib 1ribociclib 1pembrolizumab 1olaparib 1obinutuzumab 1lorlatinib 1gedatolisib 1encorafenib 1cobimetinib 1chiauranib 1capivasertib 1binimetinib 1Topotecan 1Radiotherapy 1Panobinostat 1PX-866 1NVP-BKM120 1Letrozole 1Cetuximab 1CYH33 1BAY 1895344 1AZD1390 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × Panobinostat × Clear all
NCT01341834 2018-04-24

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

National Cancer Centre, Singapore

Phase 1 Unknown
49 enrolled
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡